Lymphotoxin-alpha (LTA), a pro-inflammatory cytokine, has been implicated in the pathogenesis of coronary atherosclerosis. Meanwhile, association of some single nucleotide polymorphisms (SNPs) of LTA gene with coronary artery disease (CAD) has been evaluated; however, the results are irreproducible. We therefore investigated the relationship between four SNPs of LTA gene and CAD in Han Chinese: G+10A (rs1800683, 5′-untranslated region), A+80C (rs2239704, 5′-untranslated region), T+496C (Cys13Arg, rs2229094, exon 2), and C+804A (Thr26Asn, rs1041981, exon 3). Genotyping was performed in 438 CAD patients and 330 healthy controls. Single-locus analysis showed that the genotype and allele frequencies of G+10A polymorphism exhibited marginal differences between CAD patients and controls, although no statistical significance was observed after the Bonferroni correction. Logistic regression analysis revealed that GG genotype of G+10A polymorphism was significantly associated with the risk of CAD under the dominant mode, whereas no significant association was detected between A+80C polymorphism and CAD. In contrast, individuals carrying TT or TC genotype of T+496C polymorphism showed a decreased CAD risk relative to those with CC genotype under the recessive mode. Likewise, CC genotype of C+804A polymorphism was associated with a protective effect on CAD under the dominant mode. Further, in haplotype analysis, the haplotype G-C-T-C (in order of rs1800683, rs2239704, rs2229094 and rs1041981) was significantly associated with a decreased risk of CAD after assigning the most common haplotype A-C-T-A as a reference. In conclusion, we show a protective effect of the haplotype G-C-T-C on the occurrence of CAD, suggesting the involvement of LTA in CAD pathogenesis.
Keywords: coronary artery disease; gene; haplotype; lymphotoxin-alpha; polymorphism Tohoku J. Exp. Med., 2011 , 224 (2), 119-125. © 2011 Coronary artery disease (CAD) is a complex multifactorial disorder to which genetic and environmental factors contribute interactively; it has become one of the leading causes of death in China. Ample evidence exists proving the involvement of inflammatory processes in all phases of atherosclerotic lesion progression linked to various cytokines (Berliner et al. 1995; Ross 1999) . Lymphotoxinalpha (LTA), a pro-inflammatory cytokine, plays an important part in activating inflammatory and immunomodulatory processes, suggesting its implication in the pathogenesis of atherosclerosis and CAD (Schreyer et al. 2002; Ozaki et al. 2004) .
The LTA gene, firstly identified in 2002, was found to be independently associated with myocardial infarction (MI) in Japanese (Ozaki et al. 2002) . Subsequently, several studies confirmed the relationship between LTA gene and the risk of CAD Koch et al. 2007; Palikhe et al. 2007 ). Meanwhile, family-based linkage analyses (PROCARDIS Consortium 2004) and genome-wide association studies (Iida et al. 2003; Koch et al. 2005; Ozaki and Tanaka 2005; Tanaka and Ozaki 2006) had implicated some single nucleotide polymorphisms (SNPs) of LTA gene, such as A allele of C+804A polymorphism and C allele of T+496C polymorphism, were in predisposition to CAD or MI, but the results were not often reproducible (Clarke et al. 2006; Asselbergs et al. 2007; Park et al. 2007; Sedlacek et al. 2007; Palikhe et al. 2008; Ryan et al. 2008; Gao et al. 2010; Li et al. 2010) . Suna et al. (2008) reported that LTA stimulation might up-regulate various cytokines' expression associated with signal transduction, cell adhesion and chemoattraction, such as vascular cell adhesion molecule 1 (VCAM-1), E-selectin and monocyte chemotactic protein 1 (MCP 1) in human endothelial cells via the activation of the transcription nuclear factor of kappa light polypeptide gene enhancer in B-cells (NFkB) as in tumor necrosis factor (TNF) receptor signaling by TNF-α (a family member of LTA). Studies on the role of LTA in the procedure of monocyte adhesion to endothelial cells, which was an initial and crucial step of atherosclerosis, also raised the contribution of LTA genetic polymorphisms to the regulation of those cytokines (Suna et al. 2008 (Suna et al. , 2009 ). Asselbergs et al. (2007) revealed that the A allele of C+804A polymorphism was associated with elevated plasma level of VCAM-1 in CAD cases. It is thus of interest to confirm which or how many SNPs of LTA gene might have functional potentials to affect the final bioavailability of LTA, and further the development of CAD.
It has been postulated that some SNPs in the putative promoter, transcriptional-regular regions or coding regions could affect the efficacy of transcription or the function of protein, while haplotype analysis, which focuses on SNPs in their combination simultaneously, has a higher complexity level than single-locus analysis and more power to explore the association between candidate genes and complex disease (Rioux et al. 2001; Tabor et al. 2002; Buckland et al. 2004 ). In the present study, to explore the association of SNPs, both individually and as haplotypes, with the risk of CAD in Han Chinese, we focused on four SNPs: G+10A (rs1800683) and A+80C (rs2239704) in the 5′-untranslated region encoded by exon 1, T+496C in exon 2 (rs2229094, a non-synonymous coding SNP that substitutes arginine for cysteine at codon 13, Cys13Arg), and C+804A in exon 3 (rs1041981, a non-synonymous coding SNP resulting in a threonine to asparagine amino acid substitution at codon 26, Thr26Asn).
Materials and Methods

Study population
Our study population comprised 768 unrelated Han Chinese who were admitted to Ruijin Hospital, Shanghai Jiaotong University School of Medicine when they were experiencing various symptoms or for a medical checkup from June 2006 to June 2008. Participants were divided into 2 groups. The CAD group contained 438 patients aged 61.11 ± 9.66 years and the diagnosis of CAD was established angiographically in the presence of more than 50% stenosis in at least one of the three major coronary arteries or major branches. Patients with simple spasm of coronary arteries, myocardial bridge or other non-coronary atherosclerotic lesions were excluded. The healthy controls contained 330 participants aged 53.16 ± 7.38 years who received routine health examinations in the hospital. They had normal electrocardiographs and blood pressure, no symptoms of chest pain, and no family history of hypertension or CAD in first-degree relatives. Participants were not eligible if they had diabetes mellitus, chronic liver diseases, uremia, acute infection, autoimmune diseases or cancers. Written informed consents were obtained from each participant, and the project was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiaotong University School of Medicine. The baseline and clinical characteristics of study population are shown in Table 1 .
Genotyping analysis
Genomic DNA was extracted from peripheral blood leukocytes by standard phenol-chloroform extraction. The genotypes of four evaluated SNPs were determined by the MassARRAY technology platform (Sequenom Inc., San Diego, California, USA). The test was based on the principle of allele-specific primer extension reaction and the read-out of the result was realized on the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analytic system. All the polymerase chain reaction (PCR) primers and extension primers were designed by MassARRAY Assay Design 2.0 software according to reference sequence (NT_007592).
To provide a significant improvement in overall performance, 10-mer tag (5′-ACGTTGGATG-3′) was added to the 5′ ends of each PCR primer ( Table 2) .
The amplification mixture of total volume 5 μL contained: 1 μL of genomic DNA (10 ng/μL), 0. Inc., Valencia, California, USA). The amplification conditions were: 95°C for 15 min, followed by 45 cycles at 95°C for 20 s, 56°C for 30 s, 72°C for 1 min, then a final extension at 72°C for 3 min. Preparation for extend reaction included incubation of 5 μL PCR products with 0.3 μL shrimp alkaline phosphatase (SAP, Sequenom Inc., San Diego, California, USA) and 0.17 μL hME buffer at 37°C for 20 min, followed by heat inactivation at 85°C for 5 min.
The extension mixture contained, in a final volume of 9 μL: 7 μL of purified PCR products, 0.2 μL homogeneous MassEXTEND Mix (Sequenom Inc., San Diego, California, USA), 9 μM of each extend primer and 0.018 μL MassEXTEND enzyme (Sequenom Inc., San Diego, California, USA). The extension conditions were: 94°C for 2 min, followed by 55 cycles at 94°C for 5 min, 52°C for 5 min, 72°C for 5 min, then a final extension at 72°C for 3 min. PCR products were purified with 3 mg of clean Resin (Sequenom Inc., San Diego, California, USA) and then sequenced using MassARRAY Analyzer, version 3.0.1 (Sequenom Inc., San Diego, California, USA) on 384-well SpectroCHIP (Sequenom Inc., San Diego, California, USA).
Statistical methods
Continuous variables were expressed as mean ± standard deviation (s.d.) and compared by the unpaired Student's t-test. Genotype/allele frequencies were calculated by the counting method and the differences in genotype/allele frequencies between CAD group and healthy controls were analyzed by χ 2 test. Each genotype was assessed by logistic regression analysis assuming additive (major homozygotes vs. heterozygotes vs. minor homozygotes), dominant (major homozygotes vs. heterozygotes plus minor homozygotes) and recessive (major homozygotes plus heterozygotes vs. minor homozygotes) modes of inheritance, crude odds ratio (OR crude ) and adjusted odds ratio (OR adjusted ) and 95% confidence intervals (95% CI) were calculated as well, respectively without or with considering other covariates, including gender, age, blood pressure, the serum levels of fasting glucose and lipid profiles. To account for multiple testing, the Bonferroni method was applied. Significance would be claimed if the overall two-sided P value was < 0.05. Statistical analyses were done with SPSS 13.0 software (SPSS Inc., Chicago, Illinois, USA). Study power was calculated by PS (Power and Sample Size Calculations) software (Version 3.0) (Dupont and Plummer 1990 
Results
Clinical characteristics of the study population
Compared with healthy controls, CAD patients were older and had higher blood pressure. Also, they had higher serum levels of fasting glucose and triglycerides (TG), and lower levels of high density lipoprotein-cholesterol (HDL-C). Serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) were similar between two groups (Table 1) .
Association between LTA gene polymorphisms and CAD
For each polymorphism, the genotype/allele frequencies were in equilibrium with the Hardy-Weinberg equation. Single-locus analysis (Table 3) showed that genotype and allele frequencies of G+10A polymorphism exhibited differences between CAD patients and healthy controls (P = 0.032, 0.047, respectively); however, no significant difference was reached after the Bonferroni correction. There was no significant association between each of other three SNPs and CAD.
Logistic regression analysis (Table 4) indicated that the GG genotype of G+10A polymorphism was significantly associated with the risk of suffering CAD under the dominant mode, which preserved significance after adjustment for gender, age, blood pressure, the serum levels of fasting glucose and lipid profiles (GG vs. GA + AA: OR crude = 6.554, 95% CI: 2.129-20.174, P = 0.001; OR adjusted = 11.352, 95% CI: 1.843-69.901, P = 0.009). In contrast, individuals carrying the TT or TC genotype of T+496C polymorphism had a decreased CAD risk relative to those with the CC genotype under the recessive mode after correction (TT + TC vs. CC: OR adjusted = 0.202, 95% CI: 0.047-0.874, P = 0.032). Similarly, the CC genotype of C+804A polymorphism was associated with a protective effect on CAD under the dominant mode, even after adjusting for those confounders (CC vs. AA + CA: OR crude = 0.240, 95% CI: 0.078-0.735, P = 0.012; OR adjusted = 0.162, 95% CI: 0.026-0.997, P = 0.050). For A+80C polymorphism, we failed to observe a significant association with CAD.
Four SNPs were incorporated in the haplotype analysis, and they contributed to thirteen haplotypes in our study population. Haplotype A-C-T-A (alleles in order of rs1800683, rs2239704, rs2229094 and rs1041981) was observed comprising 40% of the total. Two additional haplotypes, G-A-T-C and G-C-C-C, had frequencies around 20-30% and haplotype G-C-T-C around 3%, whereas the remaining haplotypes were rare (frequencies less than 3%). After dropping nine rare haplotypes (data not shown), we further evaluated the remaining four haplotypes.
The frequency of haplotype G-C-T-C was significantly lower in CAD patients compared with controls (0.6% vs. 3.4%, Table 5 ). Using the most common haplotype A-C-T-A as a reference, the haplotype G-C-T-C was significantly associated with a decreased risk of CAD before and after adjustment (OR crude = 0.190, 95% CI: 0.071-0.505, P = 0.0003; OR adjusted = 0.252, 95% CI: 0.094-0.677, P = 0.0002), even after the Bonferroni correction. As for study power, our sample size was adequately powerful (97.5%) to identify this significant haplotype difference between CAD patients and controls when type I error probability for a two sided-test (α) was defined as 0.05 and OR was estimated at 1.5. Crude and d adjusted P values, OR and 95% CI are calculated using the most common haplotype A-C-T-A as a reference with the latter correcting gender, age, blood pressure, serum levels of fasting glucose, triglyceride, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol.
Discussion
In the present study, we provide evidence for an association of LTA gene polymorphisms with the risk of CAD in Han Chinese, and show a protective effect of the haplotype G-C-T-C on the occurrence of CAD, leading us to believe that LTA gene might be a logical candidate that is involved in the pathogenesis of CAD. To our knowledge, this is the first haplotype-based association study demonstrating the combined effect of LTA gene polymorphisms on susceptibility to CAD.
Lymphotoxin-alpha, a member of the tumor necrosis factor family, is an important pro-inflammatory cytokine in the inflammation process of atherosclerosis. Schreyer et al. (2002) demonstrated that LTA was expressed in atherosclerotic lesions in mice and LTA deficiency resulted in a 62% reduction in the size of the lesions. Later on, Ozaki et al. (2004) revealed that LTA was expressed in smooth muscle cells (SMCs) and macrophages in human atherosclerotic plaques, but were absent in quiescent or normal SMCs. Suna et al. (2008) also confirmed that LTA increased the expression of various genes (such as E-selectin and VCAM1) involving in the process of atherosclerosis or inflammation in human endothelial cells. These results together suggested a direct role of LTA in modulating atherosclerotic progression. Therefore, researchers sought to validate the potential effect of LTA gene on the pathogenesis of CAD.
By means of a large-scale, case-control association study, Ozaki et al. (2002) firstly confirmed a significant association between LTA gene polymorphisms and myocardial infarction in a Japanese population, which was to some degree consistent with our single-locus results supporting the involvement of A allele of C+804A polymorphism in the pathogenesis of CAD. Moreover, another large-scale study documented an independent role of C+804A polymorphism in the development of coronary atherosclerosis, showing that +804AA genotype conferred a 1.98-fold increased risk for multiple-vessel disease (Laxton et al. 2005) . Consistently, our study indicated that +804CC genotype yielded a decreased CAD risk under the dominant mode (OR = 0.240), which was further strengthened after adjustment (OR = 0.162). Functionally, Ozaki et al. (2002) indicated that C+804A polymorphism influenced mRNA expression of adhesion molecules and cytokines in the cultured human coronary artery SMCs, and +804A allele had a two-fold higher level of transcriptional activity for VCAM1 than did +804C allele. In addition, +804A allele had significantly high mRNA expression of E-selectin, whereas +804C allele did not affect its expression. Asselbergs et al. (2007) demonstrated that +804A allele was directly associated with the plasma levels of the inflammatory biomarkers and cell adhesion molecules (i.e. interleukin-6, sTNF-R2 and VCAM1). Therefore, our finding of the protective effect of +804C allele against CAD risk is consistent with its postulated function.
In addition, we found that T allele of T+496C polymorphism was protective against CAD under the recessive mode, which was reinforced by further haplotype analysis. Previous studies suggested that haplotype harboring +496C allele as a tagging SNP increased the mobility of CAD, however, +496C allele alone was not associated with CAD (Palikhe et al. 2007; 2008) . Further in vitro functional analysis conducted by the same group indicated that T+496C polymorphism caused a change of the 13 th amino acid cysteine to arginine on the signal peptide region of the mature LTA protein and +496C allele might reduce the flexibility of the signal peptide and affect its binding activity to the TNF receptor. Nevertheless, understanding the exact molecular mechanisms of T+496C polymorphism remains an open question.
However, it should be noted that although haplotype G-C-T-C was consistently confirmed as a protective factor against CAD in our study, it also carried +10G allele, which acted as a risk-conferring allele in our single-locus analysis. There were discrepant findings as to which SNPs were actually related to or responsible for this protective effect. Furthermore, other studies were unable to identify a significant association of G+10A polymorphism with CAD (Clarke et al. 2006; Sedlacek et al. 2007 ), which were in agreement with the present results after multiple corrections. We hereby reasoned that polymorphism G+10A might not be a major locus or its contribution was diluted or reversed when annexed with other loci, such as the haplotypes in the present case. Therefore, we agree that replication/validation of those LTA SNPs in larger, well-designed studies within genetic and functional framework is critical. Knight et al. (2004) had identified the A allele of A+80C polymorphism as a main predictive variable of LTA protein production by a detailed haplotype analysis of TNF/ LTA locus. Contrarily, we did not find a significant singlelocus association between CAD and A+80C polymorphism, which was one of the SNPs harboring the protective haplotype G-C-T-C. In concordance with our results, a recent meta-analysis provided reliable evidence that the A+80C polymorphism was not strongly associated with susceptibility to coronary disease (Clarke et al. 2006) .
CAD is a complex disease, which is partly due to genetic determinants. Gene-gene and gene-environment interactions are likely to contribute significantly to pathogenesis of atherosclerosis and CAD (Yamada et al. 2008; Roberts 2008) . In view of the unclear picture of LTA gene in CAD, we thus speculated that the association of LTA gene polymorphisms with CAD susceptibility might be the result of a direct functional effect of polymorphisms under study or due to their interactions with: (1) other genes or polymorphisms located in the same or neighboring genomic region, such as HLA-A, HLADRB, C4A gene in the major histocompatibility complex (MHC) region (Palikhe et al. 2007 ), BAT1-NFKBIL1-LTA region (Koch et al. 2005 (Koch et al. , 2007 and TNF/LTA locus (Iida et al. 2003; Ozaki et al. 2004; Edgel et al. 2010) ; (2) other inflammatory pathways, such as 5-lipoxygenase pathway (Bäck 2009; Cao et al. 2009 ) and leukotriene pathway (Topol et al. 2006; Crosslin et al. 2009); and (3) other proatherogenic pathways, such as lipid metabolism, blood pressure regulation, insulin resistance and cellular adhesion (Hamid et al. 2005; Topol et al. 2006; Rasouli and Kiasari 2008; Suna et al. 2009; Phillips et al. 2010) , which play an important role in the onset and development of atherosclerosis.
Interpretation of our current study, however, should be viewed in light of several limitations. A major limitation was that only four polymorphisms, whose combinations were inherited as one block in the LTA genomic region, were analyzed. Others susceptible to CAD, such as A+252G polymorphism in intron 1 ), were not under investigation. The jury must refrain from drawing a conclusion until more comprehensive studies of LTA gene are completed to confirm whether the present association is causal or due to linkage disequilibrium and illustrate whether the LTA genetic polymorphisms truly influence the susceptibility to CAD or not. Another limitation was that we had only carried out the genotype-phenotype association study, which did not adequately reveal the complex pathogenic essence of CAD. Further investigations of some intermediate phenotypes such as biomarkers of inflammation (i.e. C-reactive protein, TNF and LTA) would be helpful to identify the causality between LTA gene and CAD. Finally, molecular functional studies are warranted in the future to elucidate the crucial role of LTA gene in CAD pathogenesis.
In conclusion, our study suggests that LTA gene may be an important risk factor for the occurrence of CAD and the four SNPs may have a combined effect on the risk of CAD in Han Chinese. Our study provides an anchoring point for better understanding of the pathogenesis of CAD. Nevertheless, for practical reasons, we hope that this study will not remain just another endpoint of research instead of a beginning to establish the background data for further investigation on interaction of LTA gene and CAD in Chinese.
